



Vertically
Integrated
Sandalwood
Company



TFS Corporation Ltd

May 2015

Alistair Stevens, CFO

For personal use only



Important Notice and Disclaimer

This presentation has been prepared by TFS Corporation Ltd (**TFS**).

This presentation is not a product disclosure statement or prospectus for the purposes of the Australian *Corporations Act 2001* (Cth), nor does it constitute financial product or investment advice or a recommendation, offer or invitation by any person or to any person to sell, purchase or otherwise invest in securities in TFS in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment.

This presentation contains general information only and does not take into account the investment objectives, financial situation and particular needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser, lawyer, accountant, tax or such other adviser as considered appropriate having regard to their objectives, financial situation and needs before taking any action.

The information in this presentation contains historic information about the performance of TFS and securities in TFS (or any other financial product). That information is historic only, and is not an indication or representation about the future performance of TFS or securities in TFS (or any other financial product). You should not place undue reliance on any such information.

No representation or warranty, express or implied, is given as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty, express or implied, given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or potential returns contained in this presentation. Such forecasts, prospective statements or potential returns only reflect subjective views held by TFS, and are based on certain assumptions made by TFS, as at the date specified in the relevant information and are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of TFS. Actual events and results may vary from the events or results expressed or implied in such statements. Given these uncertainties, you should not place undue reliance on any such statements.

To the maximum extent permitted by law, TFS and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising in negligence, statute or otherwise) for any direct or indirect loss or damage which may arise or be suffered by any person through use or reliance on anything contained in, or omitted from, this presentation.

An investment in TFS securities is subject to investment and other known and unknown risks, some of which are beyond the control of TFS. TFS does not guarantee any particular rate of return or the performance of TFS securities.

The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

Section 1:

OVERVIEW



What is Indian Sandalwood?

- Indian sandalwood (*Santalum album*) is one of the world's most valuable hardwoods

- Traded commodity for over 2,000 years and declared a royal tree in India in 1792

- Value lies in the heartwood which can also be distilled into a fragrant and medicinal oil

- Sandalwood has significant cultural importance throughout Asia and is used in many worship, fragrance and chewing products

- Oil from the heartwood has proven efficacy for various skin conditions, including acne and eczema

- Oil has a fragrant aroma and has long been used in perfumery products


HEARTWOOD OF INDIAN SANDALWOOD



MATURE INDIAN SANDALWOOD TREES



TFS is a Vertically Integrated Business



For personal use only


Strong Market Position

For personal use only


- High barriers to entry
 - Planting to harvest cycle of around 15 years
 - Operational expertise and intellectual property developed over 15 years
- Strong competitive position as there are limited alternative sources of supply
 - TFS is the world's largest commercial owners and manager of Indian sandalwood
 - Declining global supply sourced from natural forests, mainly in India
- TFS owns Australia's largest sandalwood oil distillery and owns valuable IP regarding pharmaceutical grade Indian sandalwood oil
- Diverse range of high value and high volume uses and markets
 - Demand likely to increase significantly as security of supply is proven
 - Demand from oil and value-added log markets likely to add pricing tension

Favourable Supply and Demand Trends

ANNUAL GOVERNMENT SANDALWOOD HARVEST IN INDIA



INDIAN SANDALWOOD AND SANDALWOOD OIL PRICES



Sources: TFS, Tamil Nadu Forestry Department and H.S. Anantha Padmanabha

2014 - A Transformative Year for TFS

- First harvest completed in June 2014, confirming TFS's yield expectations
- Long term supply agreement with Nestle-owned Galderma for oil at US\$4,500 per kg
- First pharmaceutical product containing TFS oil launched in the US
- Record financial results with NPAT of \$82.5m in FY14




Section 2:

PLANTATION ASSETS




Plantation Assets



Underlying Value of Plantation Assets

Illustrative value chain -



Note 1: Key assumptions include: (i) survival rate – 83%, (ii) heartwood yield – average yield estimated at 20 kg per tree, (iii) expected oil yield of 3.7%, (iv) oil price of US\$4,500, and (v) FX rate of AU\$1.26 to US\$1.00.

Note 2: Gross and undiscounted yield before maintenance, harvest, processing and distribution costs.

Note 3: Value of \$1.8m per hectare is generated from all parts of the “soil to oil” value chain.

Section 3:

END MARKETS



A Broad Range of End Markets

For personal use only

- Significant established demand from India and China – Indian sandalwood is culturally important, a “cradle to grave” product
- Continued development of over-the-counter and prescription drugs containing pharmaceutical grade oil
- On-going development of a broad range of end markets, including European fine fragrance



Global demand for sandalwood in 2015

28,000t



Source: Incipient Capital report March 2014

Launch of Benzac[®] Acne Solutions

Galderma, wholly owned by Nestle, launched Benzac[®] Acne Solutions in December 2014 – already in over 23,000 stores across the US

Galderma describes Indian sandalwood oil as the “key ingredient” and a “breakthrough natural ingredient”


Source: Galderma Press Release, 5 January 2015

Orders already well in excess of one tonne of oil and a significant national marketing campaign is underway




Significant Pharmaceutical Opportunity – Acne

For personal use only



Significant Pharmaceutical Opportunity – Market

For personal use only



Clinical Examples of Efficacy of Indian Sandalwood Oil

For personal use only

Acne OTC



8 weeks

Eczema OTC



8 weeks

HPV OTC



4 weeks

Section 4:

LATEST RESULTS



Financial Results – Record Results in FY14



For personal use only

NPAT

\$82.5m

Cash EBITDA

\$51.4m

NTA

\$363.3m

Dividend

3¢ p/s

YOY Change:
+48%

-1%

+61%

-

Strong Start to FY15


NPAT (\$m)

↑ + 17x
on H1 FY14




Cash EBITDA (\$m)

↑ + 174%
on H1 FY14




Total Revenue (\$m)

↑ + 192%
on H1 FY14



NTA (\$m)

↑ + 74%
on H1 FY14



For personal use only

Summary

For personal use only



World leading owner and manager of a rare and valuable commodity



Vertically integrated business, including ownership of distillation and distribution



End markets for wood and oil are established and diversified across different sectors and territories



Already developing the significant potential of the pharmaceutical sector, with initial acne products launched in the US by Nestle-owned Galderma



Recently refreshed Board with experienced independent Non-Executive Directors



On track to achieve guidance for FY15 NPAT of at least \$90 million and a 10% year on year increase in cash EBITDA

